[go: up one dir, main page]

IN2012DN00446A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00446A
IN2012DN00446A IN446DEN2012A IN2012DN00446A IN 2012DN00446 A IN2012DN00446 A IN 2012DN00446A IN 446DEN2012 A IN446DEN2012 A IN 446DEN2012A IN 2012DN00446 A IN2012DN00446 A IN 2012DN00446A
Authority
IN
India
Prior art keywords
immunogens
compositions
tau
medicine
treatment
Prior art date
Application number
Inventor
Iii George Joseph Smith
Kenneth Nelson Wills
Jeff Xianchao Zhu
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of IN2012DN00446A publication Critical patent/IN2012DN00446A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to immunogens and compositions comprising an antigenic tau peptide, preferably linked to an immunogenic carrier for use in the treatment of tau-related neurological disorders. The disclosure further relates to methods for production of these immunogens and compositions and their use in medicine.
IN446DEN2012 2009-07-30 2010-07-20 IN2012DN00446A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
PCT/IB2010/053313 WO2011013034A1 (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00446A true IN2012DN00446A (en) 2015-05-15

Family

ID=42941871

Family Applications (1)

Application Number Title Priority Date Filing Date
IN446DEN2012 IN2012DN00446A (en) 2009-07-30 2010-07-20

Country Status (17)

Country Link
US (1) US20110177109A1 (en)
EP (1) EP2459214A1 (en)
JP (1) JP2013500326A (en)
KR (2) KR20120049900A (en)
CN (1) CN102596236B (en)
AR (1) AR078085A1 (en)
AU (1) AU2010277254B2 (en)
CA (1) CA2768346A1 (en)
CO (1) CO6612199A2 (en)
IN (1) IN2012DN00446A (en)
MX (1) MX2012001194A (en)
NZ (2) NZ618391A (en)
PE (1) PE20120817A1 (en)
RU (2) RU2518291C2 (en)
SG (1) SG177637A1 (en)
TW (2) TWI461209B (en)
WO (1) WO2011013034A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110998A1 (en) 2008-12-09 2012-02-10 Coley Pharm Group Inc IMMUNOSTIMULATORY OLIGONUCLEOTIDES
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
UA107571C2 (en) 2009-04-03 2015-01-26 PHARMACEUTICAL COMPOSITION
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Phosphonus recognition antibodies
ES2714692T3 (en) 2011-01-31 2019-05-29 Tau Bio Logic Corp Tauopathies treatment
AU2012282678B2 (en) 2011-07-11 2016-03-03 California Institute Of Technology Akt-specific capture agents, compositions, and methods of using and making
MX339762B (en) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Immunomodulator metallopeptides (immps) and compositions containing same.
MX354662B (en) 2011-10-07 2018-03-14 Ac Immune Sa Phosphospecific antibodies recognising tau.
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
SG10201913370PA (en) * 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX374811B (en) 2013-03-15 2025-03-06 Ac Immune Sa ANTI-TAU ANTIBODIES AND METHODS OF USE.
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
JP2017512751A (en) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド Tau peptides, anti-tau antibodies, and methods for their use
TWI734975B (en) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies
CN107073297B (en) 2014-07-08 2021-09-14 纽约大学 Tau imaging ligands and their use in diagnosis and treatment of tauopathies
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
ES3017796T3 (en) 2015-07-15 2025-05-13 California Inst Of Techn Il-17f-specific capture agents and methods of using
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
CN111787942B (en) * 2017-10-25 2024-03-29 杨森制药公司 Composition of phosphorylated Tau peptide and use thereof
MX2020005555A (en) * 2017-10-27 2020-08-20 United Neuroscience Tau peptide immunogen constructs.
CN109870581B (en) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 A kind of kit and method for quantitative detection of HBsAg
CN108314737B (en) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 Recombinant protein and preparation method and application thereof
CN110548135B (en) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 Phosphorylated polypeptide antigen vaccine and its preparation method and application
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
WO2020073121A1 (en) * 2018-10-07 2020-04-16 The University Of British Columbia Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
PE20211709A1 (en) * 2019-02-08 2021-09-01 Prothena Biosciences Ltd ANTIBODIES THAT RECOGNIZE TAU
KR20210125048A (en) 2019-02-08 2021-10-15 에이씨 이뮨 에스.에이. Safe Administration of Phosphorylated Tau Peptide Vaccine
US20200291391A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
BR112021021213A2 (en) 2019-04-24 2021-12-21 Ac Immune Sa Heterologous administration of tau vaccines
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
KR20220034733A (en) * 2019-05-27 2022-03-18 더 유니버시티 오브 브리티쉬 콜롬비아 Conformation-specific epitopes of tau, antibodies thereto, and methods related thereto
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
AU2021321206A1 (en) * 2020-08-07 2023-03-09 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
US20230310561A1 (en) * 2020-09-08 2023-10-05 Osaka University Immunogenic composition targeting phosphorylated tau protein
US20250340613A1 (en) * 2021-09-08 2025-11-06 Joint Stock Company «Biocad» Bispecific antibody comprising a heterodimer based on mhc proteins
JP2024538615A (en) * 2021-09-29 2024-10-23 ヤンセン ファーマシューティカルズ，インコーポレーテッド Methods for safe administration of tau phosphopeptide conjugates
CN115894659B (en) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 Microtubule-associated protein Tau antigen, and preparation method and application thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
JP2547714B2 (en) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド Oligonucleotide therapeutic agent and method for producing the same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (en) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg INSECTICIDALLY EFFECTIVE AGENT FOR CONTROLLING TEXTILE Pests
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
JPH06503821A (en) 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Vaccine based on hepatitis B surface antigen
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
EP0618968B1 (en) * 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
UA40597C2 (en) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
CN1087176C (en) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 Vaccine preparations containing 3-O deacylated monophosphoryl lipid A
DE4321946A1 (en) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonic acid esters, process for their preparation and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (en) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817854A2 (en) 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
ATE441432T1 (en) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst USE OF NON-METHYLATED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS ADJUVANTS
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE252596T1 (en) 1997-06-06 2003-11-15 Dynavax Tech Corp IMMUNO-STIMULATING OLIGONUCLEOTIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
KR100581991B1 (en) 1998-02-12 2006-05-23 이뮨 컴플렉스, 코포레이션 Modified hepatitis V core protein and derivatives thereof
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
NZ506603A (en) 1998-04-09 2002-10-25 Smithkline Beecham Biolog S Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2003519084A (en) 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
EP1123114B1 (en) 1998-10-21 2005-12-28 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virus-like particles for the induction of autoantibodies
ATE315658T1 (en) 1998-11-05 2006-02-15 Powderject Vaccines Inc GENETIC CONSTRUCTS FOR GENIMUNIZATION
IL143441A0 (en) 1998-11-30 2002-04-21 Cytos Biotechnology Ag Non-naturally occuring antigen arrays and processes for the preparation thereof
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
CZ20021043A3 (en) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Use of polyoxyethylene sorbitan ester in combination with an octoxynol for preparing an auxiliary agent
KR20020048942A (en) 1999-09-24 2002-06-24 장 스테판느 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one nonionic surfactant
ATE336502T1 (en) 2000-04-07 2006-09-15 Univ Leeds HEPATITIS B CORE PROTEIN FUSION PROTEINS
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1294893B1 (en) 2000-06-22 2006-03-15 UCB Pharma Limited Modification of hepatitis b core antigen
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (en) 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
NZ538083A (en) 2002-07-17 2006-08-31 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ537688A (en) * 2002-07-19 2007-01-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays for treating and/or attenuating Alzheimer's disease
WO2004053091A2 (en) 2002-12-10 2004-06-24 Lorantis Ltd. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
DK1701968T3 (en) * 2003-12-17 2015-06-22 Wyeth Llc THE IMMUNOGENE PEPTID-CARRIER CONJUGATES AND PROCEDURES FOR THEIR PREPARATION
WO2006134423A2 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
BRPI0518151A2 (en) * 2004-10-13 2009-06-16 Ablynx Nv polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
ES2348312T3 (en) * 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. HER-2 / NEU VACCINE BASED ON MULTIPLE PEPTIDES.
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EP2440234A4 (en) * 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
FR3058624B1 (en) 2016-11-15 2018-12-07 L'oreal BRUSH FOR APPLYING A PRODUCT ON THE LASHES AND / OR THE EYE

Also Published As

Publication number Publication date
CN102596236A (en) 2012-07-18
NZ618391A (en) 2015-07-31
RU2014112002A (en) 2015-10-10
RU2012102701A (en) 2013-09-10
TW201436804A (en) 2014-10-01
SG177637A1 (en) 2012-03-29
KR20130127547A (en) 2013-11-22
TWI461209B (en) 2014-11-21
US20110177109A1 (en) 2011-07-21
CA2768346A1 (en) 2011-02-03
MX2012001194A (en) 2012-03-07
WO2011013034A4 (en) 2011-04-28
EP2459214A1 (en) 2012-06-06
RU2518291C2 (en) 2014-06-10
KR20120049900A (en) 2012-05-17
TW201106968A (en) 2011-03-01
AU2010277254A1 (en) 2012-02-09
CO6612199A2 (en) 2013-02-01
CN102596236B (en) 2015-06-24
JP2013500326A (en) 2013-01-07
AU2010277254B2 (en) 2015-05-07
WO2011013034A1 (en) 2011-02-03
AR078085A1 (en) 2011-10-12
PE20120817A1 (en) 2012-07-07
NZ598356A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
IN2012DN00446A (en)
PH12016500040A1 (en) Pcsk9 vaccine
PH12013501636A1 (en) Treatment of osteoarthritis and pain
MX2011007930A (en) Crystalline insulin-conjugates.
IN2012DN01920A (en)
TN2012000414A1 (en) Forms of rifaximin and uses thereof
IN2012DN02645A (en)
IN2012DN02737A (en)
MX337723B (en) IgE CH3 PEPTIDE VACCINE.
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
AU2010329805B2 (en) New conjugates and compositions for immunotherapy and anti-tumoral treatment
MX354481B (en) DKK1 ANTIBODIES and METHODS OF USE.
TN2011000374A1 (en) Antibody molecules having specificity for human ox40
IN2012DN02081A (en)
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX359854B (en) Anti-cxcr3 antibodies.
MX2013011421A (en) Pyrazolo pyrimidine derivatives.
UA102515C2 (en) Novel dosage form
MY150931A (en) Substituted oxazolidinones and their use
GB201118201D0 (en) Novel peptides
MX2011012505A (en) Substituted piperidines.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
MX2009009361A (en) Novel dosage form.